UnknownPhase 2

OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

Saudi Arabia220 participantsStarted 2018-01-01

Plain-language summary

This is a prospective, multi-center, open-label, phase II clinical trial, aims to assess the effectiveness of the combination ACVD (Adriamycin, Cyclophosphamide, Vinblastine and Dacarbazine) and BV (Brentuximab Vedotin) in PET-2 positive advanced-stage HL patients, in order to improve the overall long-term disease control in the entire cohort of advanced-stage HL.

Who can participate

Age range14 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Heart failure with LVEF \<50%
✕. Liver enzymes, \>2 ULN not attributed to Hodgkin Lymphoma.
✕. Another malignancy that is currently clinically significant or requires active intervention

What they're measuring

]Progression Free Survival (PFS)

Timeframe: 3 years

Trial details

NCT IDNCT03527628

SponsorKing Abdullah International Medical Research Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-01-15

Contact for this trial

Ayman Alhejazi, MD

801 1111 hejazia@ngha.med.sa

View on ClinicalTrials.gov More Classical Hodgkin Lymphoma trials